Company history

Ion-exchange research stopped with the war, but Maruyama Masatake, who had led it in the pharmaceutical department of the Army Medical School, was certain of its future. In October 1945 he bought resin from Mitsubishi Chemical’s Kurosaki works and restarted; by February 1946 he had a demineralizer producing forty litres an hour. To make and sell it he took over Yamanashi Kagaku Kogyo and, on 1 May 1946, launched Nihon Organo Shokai in Suwa, Nagano, with ¥50,000 of capital — the first company in Japan whose main line of goods was ion-exchange equipment. The name came from the term then used for the resins, organolite.

The insight built into the business from day one was that resin alone gives a customer nothing. Value lay in designing the vessel, packing it, installing it and delivering water — so Organo did all of it. In the shortage years that meant the entire board stuffing resin cylinders into rucksacks and riding packed trains to Tokyo, Osaka and Nagoya to sell and to collect payment. Sales tripled between 1946 and 1947 and were forty times the founding level by 1951.

That year the company proved the case decisively. A 600-tonne-per-day monobed system delivered to Showa Denko’s Okawa works — among the largest in the world — cut the cost of a tonne of water from ¥500 by distillation to ¥30, and the labour from eighteen people to one man on rounds. A 1951 alliance with America’s Rohm and Haas secured the resin supply; in 1957, working with NEC, Organo completed Japan’s first high-purity water plant for the electronics industry — the beginning of ultrapure water, and of a customer base that would eventually define the company. Reverse osmosis was added from 1972. Meanwhile a chain of regional subsidiaries — sales, construction, then maintenance — was laid across the country, and in March 1985 the company moved up to the first section of the Tokyo exchange.

When Japanese semiconductor and component makers shifted production to Southeast Asia in the 1980s, the demand for pure water went with them. Organo opened in Malaysia in January 1986 and Thailand in 1989, and built its second domestic plant at Tsukuba the same year. The overseas network was not a diversification but a consequence: the company goes where its customers build.

The 1990s were spent tidying the group — construction and maintenance subsidiaries merged step by step into Organo Plant Service by 1996 — while Tosoh held its position as the largest shareholder and presidents began to be drawn from its ranks. In September 2003 Organo entered China with a subsidiary in Suzhou, at the centre of the Yangtze delta’s electronics cluster, as fabs and panel plants went up across the mainland. The 2008 financial crisis cut consolidated revenue from ¥73.1bn to ¥53.5bn in a single year, but the Asian network was kept intact, and Vietnam (2010) and Indonesia (2013) were added.

The business itself settled into two halves that still describe it: functional products — resins and chemicals, small but steadily profitable — and water-treatment engineering, which by FY2014 was three times larger at ¥53.3bn against ¥15.3bn. Within engineering, ultrapure water and chemical-supply systems for electronics had become the core. The customer industry had migrated across seventy years from power stations and chemical plants to semiconductor fabs, without the company ever changing what it actually does.

In April 2014 Organo absorbed seven regional sales subsidiaries at once — Hokkaido, Tohoku, Tokyo, Chubu, Kansai, Kyushu and Yamashita Yakuhin — closing in a single stroke the dispersed structure begun with Nihon Degremont in 1959. The reasoning was that customers’ domestic plants were consolidating or moving offshore, so the advantage of a locally staffed presence had faded; better to concentrate resources and run one national sales organization. Governance stayed where it was: Tosoh held 41.2% in FY2015 and around 44% by FY2024, and every president since 2010 has come from it, an unusual arrangement of a listed subsidiary under a listed parent.

What followed was a decade of structural growth handed to Organo by the semiconductor industry. Revenue rose from ¥68.7bn with ¥2.4bn of operating profit in FY2014 to ¥92.2bn and ¥6.6bn in FY2018, then accelerated: ¥100.6bn and ¥9.6bn in FY2020, ¥132.4bn and ¥15.2bn in FY2022, and ¥163.2bn with ¥31.1bn of operating profit in FY2024 — 2.4 times the revenue and roughly thirteen times the operating profit of a decade earlier. The Asian network built since 1986 absorbed the investment wherever it landed.

The next geography was decided the same way. Leading-edge capacity had consolidated into TSMC, Samsung and Intel, single fabs had grown from hundreds of billions of yen to over a trillion, and Washington had begun pushing chipmaking back onshore — so in September 2021 Organo established Organo USA, adding the Americas to a foreign network that had been strictly Asian for thirty-five years, ahead of plants due to start up from 2023. The company moved to the TSE Prime market in 2022 and absorbed another subsidiary, Organo Ecotechno, in 2024. Eighty years of ion-exchange know-how are now pointed almost entirely at one customer industry — which is both the source of the growth and the whole of the risk.